The Brastianos laboratory studies molecular drivers of human brain tumors. A lack of understanding of the molecular drivers of many brain tumors has hampered the development of novel therapies for many brain cancers. Our overarching objective is to characterize the tumor and immune microenvironment in primary brain tumors and brain metastases, and accelerate the development of novel therapeutic approaches for these diseases. We recently discovered clinically significant genetic drivers in meningiomas, craniopharyngiomas, hemangioblastomas, glioneuronal tumors and brain metastases. We are currently investigating the role of these genomic drivers as potential therapeutic targets in several national NCI-sponsored multi-center clinical trials. Additionally, we are expanding our in vitro and in vivo investigations to further elucidate the molecular evolution of the metastatic process to the central nervous system.
Craniopharyngiomas are a rare brain tumor that can cause profound clinical sequelae both through mass effect at presentation and through morbidity of treatment. Historically, incomplete knowledge of the molecular mechanisms that drive craniopharyngiomas has limited the development of targeted therapies for this tumor. We recently comprehensively characterized the molecular drivers of craniopharyngiomas. We identified activating mutations in CTNNB1 in nearly all adamantinomatous craniopharyngiomas and recurrent mutations in BRAF (resulting in p.Val600Glu) in nearly all papillary craniopharyngiomas (Brastianos et al. Nature Genetics 2014). These findings have important implications for the diagnosis and treatment of these neoplasms. We initiated a national multicenter trial in craniopharyngiomas (Alliance A071601) to investigate the role of targeted therapies in these tumors. In patients with newly diagnosed papillary craniopharyngioma, we showed that all patients who received one or more cycles of vemurafenib/cobimetinib had dramatic responses to therapy (Brastianos et al. NEJM 2023)
Meningiomas are the most common primary nervous system tumor with no known effective systemic therapy. Recently, we comprehensively characterized meningiomas and demonstrated that meningiomas harbor recurrent oncogenic clinically actionable mutations in AKT1 (E17K) and SMO (W535L) (Brastianos et al. Nature Genetics 2013). Notably, these mutations were present in therapeutically challenging tumors of the skull base. We also recently identified potential genetics drivers of progression in meningiomas (BAP1, TERT promoter mutations, DMD). Our lab is working on developing better preclinical models of meningioma with the goal of testing new therapeutic targets in this disease. We are now conducting a prospective national multicenter Phase 2 study (A071401) of targeted therapy in patients with recurrent or progressive meningiomas harboring clinically actionable mutations, respectively (Brastianos et al. JCO 2023).
Brain metastases are a common complication of cancer, with a dismal prognosis. There is a limited understanding of the oncogenic alterations harbored by brain metastases and whether these are shared with their primary tumors or other metastatic sites.
The objectives of the Central Nervous System Metastasis Center are to:
We are comprehensively characterizing the tumor and immune microenvironment of brain metastases to understand how they evolve in the CNS. We have demonstrated that brain metastases harbor clinically actionable drivers not detected in the primary tumors (Brastianos, Carter et al. Cancer Discovery 2015). We are evaluating the roles of these genetic alterations using various assays of metastasis (Shih, Nayyar et al. Nature Genetics 2020) and inhibiting pathways commonly altered in brain metastases with novel therapies. In addition, using single-cell RNA sequencing, we are characterizing the dynamic changes in immune microenvironment during treatment (Prakadan et al. Nature Communications 2021). Based on the work in the lab, we have now initiated a national genomically guided brain metastasis trial (A071701). Our hope is that the findings from our genomic and functional investigations will allow us to develop more rational therapeutic approaches for this disease.
Selected Publications
Brastianos PK et al. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126.
Alvarez-Breckenridge C, .. Brastianos PK**, Carter SL.** Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition. Cancer Immunol Res. 2022 Jun 15:canimm.CIR-21-0870-E.2021.
Prakadan SM, Alvarez-Breckenridge C.A., Markson SC, … Carter SL**, Brastianos PK**, Shalek AK**. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat Commun. 2021 Oct 12;12(1):5955
Brastianos PK*, Kim AE*, et al. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nature Cancer. 2021; May;2 (5):498-502.
Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D'Andrea MR, Chukwueke U, Ippen FM, Alvarez-Breckenridge C, Camarda ND, Lastrapes M, McCabe D, Kuter B, Kaufman B, Strickland MR, Martinez-Gutierrez JC, Nagabhushan D, De Sauvage M, White MD, Castro BA, Hoang K, Kaneb A, Batchelor ED, Paek SH, Park SH, Martinez-Lage M, Berghoff AS, Merrill P, Gerstner ER, Batchelor TT, Frosch MP, Frazier RP, Borger DR, Iafrate AJ, Johnson BE, Santagata S, Preusser M, Cahill DP, Carter SL*, Brastianos PK*. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 Apr;52(4):371-377.
*co-first authors
**co-senior authors
Learn more about the people working in our lab.
